Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Small Cell 1Breast Neoplasms 1

Interventions

Specimen Handling 34Carboplatin 32pembrolizumab 28Pemetrexed 27Magnetic Resonance Spectroscopy 27Cisplatin 22Paclitaxel 15durvalumab 13Gemcitabine 13Docetaxel 12osimertinib 11Nivolumab 11atezolizumab 8Immunoglobulin G 8Disulfides 8Taxes 7Etoposide 7130-nm albumin-bound paclitaxel 7Radiotherapy 6Radiosurgery 6Radiation 6Platinum 6Cetuximab 6Biopsy 6X-Rays 51,2-diaminocyclohexaneplatinum II citrate 5Ramucirumab 4Observation 4Irinotecan 4Interviews as Topic 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × EC regimen × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡